What a 2026 obesity-drug review found

A 2026 scoping review of anti-obesity medicines finds that incretin-based drugs, medicines that act on gut-hormone pathways involved in appetite and glucose regulation, produced the largest weight-loss results in the studies it included. The review covered 42 articles representing 41 unique studies, mostly randomised controlled trials, found through PubMed and Scopus in May 2025.^[1] That is a useful map of a fast-moving field, but it is not a prescription or a head-to-head answer for any individual person.

The review puts incretin drugs at the centre

The review grouped medicines by how they work. It included GLP-1 receptor agonists such as semaglutide, multi-receptor incretin agonists such as tirzepatide and retatrutide, amylin-based combinations, older non-incretin medicines, microbiome-targeted approaches and nutraceuticals. In the review's summary, GLP-1 receptor agonists showed about 10% to 16% weight loss, while tirzepatide showed about 15% to 21% over treatment periods of 20 to 70 weeks.^[1]

Those ranges are summaries across different trials, not a forecast. Trials enroll defined populations, use set protocols and compare a medicine with a particular control. The review itself notes that emerging multi-receptor medicines had promising results, while evidence for several newer pharmacotherapies and other approaches remained limited.^[1] A percentage taken from a review cannot tell a reader what will happen outside a trial.

The individual trials explain the range

A large semaglutide trial helps show why the review gives a range rather than one headline number. In STEP 1, 1,961 adults with overweight or obesity and no diabetes were assigned to semaglutide or placebo alongside lifestyle intervention. At week 68, mean body-weight change was minus 14.9% with semaglutide and minus 2.4% with placebo.^[2] The trial administered treatment once weekly. It did not establish a personal regimen for readers.

The review's upper end also reflects trials of medicines with more than one receptor target. Retatrutide activates GIP, GLP-1 and glucagon receptors. In a 48-week phase 2 trial involving 338 adults with obesity, the 12 mg group had a least-squares mean body-weight change of minus 24.2%, compared with minus 2.1% with placebo.^[3] This was an early, dose-ranging trial, so it should not be read as proof of long-term safety or as an approved treatment recommendation.

Readers following retatrutide. A phase 2 result can establish a signal in a selected research population. It cannot settle durability, uncommon harms, access or how the medicine compares with every existing option. The scoping review reaches a similar conclusion when it calls for more comparative trials, mechanistic work and long-term real-world research.^[1]

Safety appears in the same evidence, not beside it

The review identifies gastrointestinal adverse events as the most frequently reported events across incretin-based therapies.^[1] Individual trial reports add the needed detail. In STEP 1, nausea and diarrhoea were the most common adverse events with semaglutide, and discontinuation because of gastrointestinal events occurred in 4.5% of participants receiving semaglutide and 0.8% receiving placebo.^[2]

In the retatrutide phase 2 trial, gastrointestinal adverse events were the most common and were dose-related; the report also described dose-dependent increases in heart rate that peaked at 24 weeks and declined later.^[3] These observations are part of the benefit-risk picture. They are not a reason to assume that every medicine in the class has the same frequency, severity or long-term safety profile.

What the review does not settle

A scoping review maps a broad literature. It does not replace a systematic comparison of like-for-like trials, and the included evidence spans different medicines, durations and populations. The authors describe older non-incretin medicines, microbiome-focused treatments and nutraceuticals as having more modest or more variable results than the incretin-based therapies in their review.^[1] That description is not evidence that every member of one group is better for every outcome or person.

The review also cannot answer the questions that emerge only with time: whether weight change is maintained after treatment changes, which harms are uncommon, and how results translate to routine care. Its literature search was conducted in May 2025, so later studies are outside its evidence base.^[1] Readers considering an anti-obesity medicine need an individual clinical discussion that accounts for medical history, other medicines and the current product label.

The authors searched for original studies published in the five years before their search, then synthesised a mixed evidence base rather than pooling a single common endpoint. That approach is useful for seeing the field's breadth. It also means the reported ranges sit beside differences in trial duration, comparator, eligibility criteria and outcome reporting.^[1] A reader should keep those differences in view before comparing one headline result with another.

Why this review is useful

The review checks two bad shortcuts. One is treating a single dramatic trial result as a verdict on an entire drug class. The other is treating all weight-loss medicines as interchangeable. Its synthesis points to strong trial results for incretin-based medicines while keeping the remaining evidence gaps visible.^[1] For the underlying studies and current status of individual compounds, start with the linked peptide pages rather than a social-media claim or a product pitch.